Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Meta-analysis suggests ibrutinib is safe, effective in DLBCL

Key clinical point: The pooled median progression-free and overall survival were 4.54 months and 11.5 months, respectively.

Major finding: The relapsed/refractory DLBCL achieved a pooled OR and CR of 49.7 % and 27.7 %, respectively.

Study details: Meta-analysis of 854 patients with DLBCL from 13 studies.

Disclosures: The study was supported by the Beijing Municipal Natural Science Foundation. The authors reported that they had no conflicts.


Hou K et al. Critical Reviews in Oncology/Hematology. 2020;